Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Recommendation of “Hold” from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been given a consensus recommendation of “Hold” by the seven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $5.60.

A number of research analysts recently commented on PSTV shares. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Lake Street Capital began coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price objective on the stock. Finally, Wall Street Zen upgraded Plus Therapeutics to a “sell” rating in a research report on Saturday.

Plus Therapeutics Stock Performance

Shares of NASDAQ PSTV opened at $3.56 on Tuesday. The business has a 50-day moving average of $0.39 and a 200-day moving average of $0.50. The firm has a market capitalization of $24.43 million, a price-to-earnings ratio of -0.11 and a beta of 1.03. Plus Therapeutics has a 12 month low of $3.23 and a 12 month high of $30.50.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Thursday, March 12th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.28. The company had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $1.23 million. On average, analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PSTV. Susquehanna International Group LLP bought a new position in shares of Plus Therapeutics during the 3rd quarter valued at $46,000. Jane Street Group LLC bought a new stake in Plus Therapeutics in the second quarter worth $41,000. State Street Corp lifted its stake in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the last quarter. Scientech Research LLC purchased a new stake in Plus Therapeutics during the third quarter valued at about $100,000. Finally, XTX Topco Ltd purchased a new stake in Plus Therapeutics during the fourth quarter valued at about $127,000. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.